Wedbush Securities, Inc. (Investm… recently announced the acquisition of new stake in InspireMD Inc. (AMEX:NSPR). The institutional investor has increased its shareholding in the Healthcare company by 211.63% to 0.12 million shares with purchase of 81838.0 shares. This fresh investment now brings its stake to 1.01% valued currently at $56036.0. In addition, Barclays Capital, Inc. raised its holdings by 454.0 to 28929.0 shares. And Bellevue Asset Management LLC has lifted its position by 91.67% or 22.0 shares – to 46.0 shares.
With over 0.77 million InspireMD Inc. (NSPR) shares trading Friday and a closing price of $0.46 on the day, the dollar volume was approximately $0.35 million. The shares have shown a negative weekly performance of -10.10% and its price on 07/31/20 lost nearly -3.39%. Currently, there are 4.62M common shares owned by the public and among those 4.31M shares have been available to trade.
An analysis of what Wall Street brokers have to say about the expected price targets for this stock gives us this picture: 1 analysts who have offered their price forecasts for NSPR have a consensus price objective of $2.00. The analysts have set the share’s price value over the next 12 months at a high of $2.00 and a low of $2.00 should the stock experience a downside. But an upside of 77.0% will see the stock hit the forecast high price target while mean target price for the stock is $2.00.
Insiders at the company have transacted a total of 3 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 3 of these insider trades were purchases, accounting for 287,931 shares. Insider sales of the common stock occurred on 0 occasions, with total insider shares sold totaling 0 shares.
Bridgeway Ultra Small Company Mar owns 25000.0 shares of the company’s stock, all valued at over $11625.0. The company bought an additional 25000.0 shares recently to bring their total holdings to about 0.21% of the shares outstanding.
Shares of InspireMD Inc. (AMEX: NSPR) opened at $0.45, down -$0.02 from a prior closing price of $0.47. However, the script later closed the day at $0.46, down -3.39%. The company’s stock has a 5-day price change of -10.10% and -37.21% over the past three months. NSPR shares are trading -57.56% year to date (YTD), with the 12-month market performance down to -86.11% lower. It has a 12-month low price of $0.39 and touched a high of $5.30 over the same period. Currently, 0.77 million shares have been traded, compared to an average intraday trading volume of 4.52 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -4.43%, -17.58%, and -45.47% respectively.
Institutional ownership of InspireMD Inc. (AMEX: NSPR) shares accounts for 0.90% of the company’s 4.62M shares outstanding. Mutual fund holders own 2.17%, while other institutional holders and individual stakeholders account for 20.08% and 0.27% respectively.
It has a market capitalization of $15.46M and a beta (3y monthly) value of 2.26. The earnings-per-share (ttm) stands at -$3.85. Price movements for the stock have been influenced by the stock’s volatility, which stands at 6.63% over the week and 7.84% over the month.
Analysts forecast that InspireMD Inc. (NSPR) will achieve an EPS of -$0.35 for the current quarter, -$0.28 for the next quarter and -$1.02 for 2021. The lowest estimate earnings-per-share for the quarter is -$0.35 while analysts give the company a high EPS estimate of -$0.35. Comparatively, EPS for the current quarter was -$1.59 a year ago. Earnings per share for the fiscal year are expected to increase by 71.20%, and 21.50% over the next financial year.
Specifically, 1 Wall Street analysts polled rate the stock as a buy, while 0 of the 1 advise that investors “hold,” and 0 rated it as a “Sell.”
Looking at the support for the NSPR, a number of firms have released research notes about the stock. Rodman & Renshaw stated their Buy rating for the stock in a research note on January 07, 2016, with the firm’s price target at $4. Oppenheimer coverage for the InspireMD Inc. (NSPR) stock in a research note released on March 13, 2015 offered a Perform rating with a price target of .